Literature DB >> 32893964

Benign prostatic hyperplasia - what do we know?

Conor M Devlin1,2, Matthew S Simms2, Norman J Maitland1.   

Abstract

OBJECTIVES: To present historical and contemporary hypotheses on the pathogenesis of benign prostatic hyperplasia (BPH), and the potential implications for current medical therapies.
METHODS: The literature on BPH was reviewed. BPH is a prevalent disease with significant health and economic impacts on patients and health organisations across the world, whilst the cause/initiation of the disease process has still not been fully determined.
RESULTS: In BPH, pathways involving androgens, oestrogens, insulin, inflammation, proliferative reawakening, stem cells and telomerase have been hypothesised in the pathogenesis of the disease. A number of pathways first described >40 years ago have been first rebuked and then have come back into favour. A system of an inflammatory process within the prostate, which leads to growth factor production, stem cell activation, and cellular proliferation encompassing a number of pathways, is currently in vogue. This review also highlights the physiology of the prostate cell subpopulations and how this may account for the delay/failure in treatment response for certain medical therapies.
CONCLUSION: BPH is an important disease, and as the pathogenesis is not fully understood it impacts the effectiveness of medical therapies. This impacts patients, with further research potentially highlighting novel therapeutic avenues.
© 2020 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International.

Entities:  

Keywords:  #UroBPH; benign prostatic hyperplasia; growth factors; hormones; inflammation; telomerase; treatment

Year:  2020        PMID: 32893964     DOI: 10.1111/bju.15229

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  16 in total

Review 1.  Prostate luminal progenitor cells: from mouse to human, from health to disease.

Authors:  Manon Baures; Charles Dariane; Elisavet Tika; Emilia Puig Lombardi; Nicolas Barry Delongchamps; Cedric Blanpain; Jacques-Emmanuel Guidotti; Vincent Goffin
Journal:  Nat Rev Urol       Date:  2022-01-25       Impact factor: 14.432

2.  Features of patients referring to the outpatient office due to benign prostatic hyperplasia: analysis of a national prospective cohort of 5815 cases.

Authors:  Paola Irene Ornaghi; Angelo Porreca; Marco Sandri; Alessandro Sciarra; Mario Falsaperla; Giuseppe Mario Ludovico; Maria Angela Cerruto; Alessandro Antonelli
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-07-22       Impact factor: 5.455

Review 3.  Role of prostate stem cells and treatment strategies in benign prostate hyperplasia.

Authors:  Kalyan J Gangavarapu; Peter F Jowdy; Barbara A Foster; Wendy J Huss
Journal:  Am J Clin Exp Urol       Date:  2022-06-15

4.  Same-day discharge following minimally invasive partial and radical nephrectomy: a National Surgical Quality Improvement Program (NSQIP) analysis.

Authors:  Krishna Teja Ravivarapu; Evan Garden; Chih Peng Chin; Micah Levy; Osama Al-Alao; Joseph Sewell-Araya; Alexander Small; Reza Mehrazin; Michael Palese
Journal:  World J Urol       Date:  2022-07-30       Impact factor: 3.661

5.  Prostatic artery embolization in people with spinal cord injury: a safe and effective technique to ease intermittent catheterization in case of concomitant benign prostatic hyperplasia.

Authors:  Gianluca Sampogna; Fabiane Barbosa; Pietro Maria Brambillasca; Emanuele Montanari; Antonio Rampoldi; Michele Spinelli
Journal:  Spinal Cord Ser Cases       Date:  2022-03-25

6.  Rauwolfia vomitoria extract suppresses benign prostatic hyperplasia by inducing autophagic apoptosis through endoplasmic reticulum stress.

Authors:  Guifang Huang; Xiao He; Zesheng Xue; Yiming Long; Jiakuan Liu; Jinming Cai; Pengfei Tang; Bangmin Han; Bing Shen; Ruimin Huang; Jun Yan
Journal:  BMC Complement Med Ther       Date:  2022-05-05

7.  Dihydroartemisinin attenuates benign prostatic hyperplasia in rats by inhibiting prostatic epithelial cell proliferation.

Authors:  Bo Zhang; Xiang Chen; Yu Gan; Bing-Sheng Li; Kang-Ning Wang; Yao He
Journal:  Ann Transl Med       Date:  2021-08

8.  Aescin Protects against Experimental Benign Prostatic Hyperplasia and Preserves Prostate Histomorphology in Rats via Suppression of Inflammatory Cytokines and COX-2.

Authors:  Mohamed Raafat; Amr A Kamel; Alaa H Shehata; Al-Shaimaa F Ahmed; Asmaa M A Bayoumi; Rabab A Moussa; Mohammed A S Abourehab; Mahmoud El-Daly
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-22

9.  Potential role of glutathione S-transferase P1 gene polymorphism and metabolic syndrome in lower urinary tract symptoms attributed to benign prostatic hyperplasia.

Authors:  Wenjun Zhang; Zheming Li; Miao Liu; Yi Mu; Jun He; Pan Chen; Dongdong Liu; Kehang Chen; Bangwei Che; Shenghan Xu; Hongyan Zhang; Kaifa Tang
Journal:  World J Urol       Date:  2021-07-06       Impact factor: 4.226

Review 10.  The Etiology and Pathophysiology Genesis of Benign Prostatic Hyperplasia and Prostate Cancer: A New Perspective.

Authors:  Teow J Phua
Journal:  Medicines (Basel)       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.